Valneva Faces a Triple Threat: Legal Probe, Analyst Downgrades, and a Stalled Clinical Endpoint

Valneva shares hit 52-week low after Phase 3 Lyme vaccine miss, Goldman Sachs downgrade, and securities fraud probe; analysts split on outlook.

The French vaccine developer Valneva is navigating one of its most turbulent periods in recent memory, with its stock trading at €2.35 in Frankfurt — just a hair above its 52-week low and roughly 55% below the year’s peak. The shares have shed around 39% since January, and the 200-day moving average of €3.94 now sits more than 40% above the current price. What was once a story of pipeline promise has become a test of resilience, as the company confronts a failed clinical milestone, a looming investor lawsuit, and a Wall Street bank that has turned decisively bearish.

A Statistical Miss That Changed Everything

The root of the trouble lies in the VALOR Phase 3 study for VLA15, the Lyme disease vaccine candidate developed in partnership with Pfizer. The data showed a vaccine efficacy of 73.2% after the fourth dose — a figure that, on its face, looks clinically meaningful. But the pre-specified statistical hurdle required a 95% confidence interval with a lower bound above 20. The actual result delivered an interval ranging from 15.8 to 93.5. The primary endpoint was missed.

Valneva and Pfizer have nonetheless framed the outcome as positive, arguing that the totality of clinical evidence — strong efficacy and a clean safety profile — should persuade regulators. They plan to submit the data to the FDA and EMA in the second half of 2026. But the market has not been convinced. On the day of the announcement, Valneva’s U.S. depositary receipts plunged roughly 37%.

That sharp sell-off has now attracted legal attention. The U.S. law firm Pomerantz LLP announced on April 26 that it is investigating potential securities fraud claims against Valneva and certain executives, focusing on the gap between the company’s upbeat messaging and the missed endpoint. Whether the probe leads to a formal class-action suit remains uncertain, but it adds another layer of uncertainty to an already fragile stock.

Goldman Turns Bearish, Others Stay Bullish

Goldman Sachs downgraded Valneva to “Sell” on April 22, slashing its price target to $4.90 (roughly €2.15 in local terms). The bank cited an unclear regulatory path for the Lyme vaccine and a lack of near-term catalysts, pointing to recent setbacks including the withdrawal of the Chikungunya vaccine IXCHIQ from the U.S. market. Goldman also flagged structural issues: a negative gross margin of 10% and EBITDA losses of $76 million over the past twelve months.

Wall Street Zen followed a day later with a “Strong Sell” rating. The consensus among analysts now stands at “Hold,” with an average price target of $11.98 — a level that feels distant given the stock’s current trajectory.

But not everyone is running for the exits. Jefferies maintains a price target of $15.00, while Guggenheim rates the stock a “Buy” with an $11.00 target. Guggenheim expects first-quarter 2026 total revenue of €49.1 million, well above the market consensus of €45.1 million. The bulls argue that Pfizer’s continued involvement lends strategic credibility, and that the regulatory story is far from over.

Cash, Commercials, and the Calendar

While the regulatory drama plays out, Valneva’s commercial products — the travel vaccines Ixiaro and Dukoral — must keep the lights on. For the full year 2025, the company reported total revenue of €174.7 million and year-end liquidity of €109.7 million. That provides a cushion, but regulatory filings are expensive and time-consuming.

The next major checkpoint comes on May 7, when Valneva reports first-quarter 2026 results. Investors will be watching closely to see whether commercial momentum is holding up and how much financial runway remains for the regulatory submissions. Later in the year, the market also expects Phase 2 data on the Shigella vaccine candidate — a potential pipeline catalyst that could shift the narrative.

For now, Valneva’s story hinges on a single question: Can a vaccine that missed its statistical target still win regulatory approval? The answer will determine whether the stock is a deep-value opportunity or a value trap. The next few months will provide crucial clues.